Eli Lilly is set to acquire Calytrix Bio in a deal worth up to $1.5 billion. Calytrix is a privately held biotechnology company backed by JPMorgan Chase, and it is developing therapies for rare blood cancers.
Quartz and The Wall Street Journal both describe Calytrix’s pipeline as focused on rare blood malignancies, with Quartz adding that the acquisition covers Calytrix’s preclinical antibody work for essential thrombocythemia and myelofibrosis, including milestone payments. BioPharma Dive frames the purchase as part of Lilly’s broader acquisition activity, describing it as Lilly’s 15th announced company acquisition of the year and linking the program to precision therapy for myeloproliferative neoplasms.
Across the coverage, outlets agree on the deal’s maximum value and Calytrix’s rare blood cancer focus, while they differ in emphasis—some concentrate on the specific asset and payments, and others highlight Lilly’s recent buyout pace and sector context.